Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
582.34
-1.39 (-0.24%)
At close: Dec 31, 2025, 4:00 PM EST
581.00
-1.34 (-0.23%)
After-hours: Dec 31, 2025, 7:13 PM EST
Madrigal Pharmaceuticals Market Cap
Madrigal Pharmaceuticals has a market cap or net worth of $13.23 billion as of December 31, 2025. Its market cap has increased by 99.14% in one year.
Market Cap
13.23B
Enterprise Value
12.46B
1-Year Change
99.14%
Ranking
Category
Stock Price
$582.34
Market Cap Chart
Since March 28, 2007, Madrigal Pharmaceuticals's market cap has increased from $288.50M to $13.23B, an increase of 4,484.32%. That is a compound annual growth rate of 22.60%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 31, 2025 | 13.23B | 96.52% |
| Dec 31, 2024 | 6.73B | 47.33% |
| Dec 29, 2023 | 4.57B | -7.98% |
| Dec 30, 2022 | 4.96B | 242.65% |
| Dec 31, 2021 | 1.45B | -15.74% |
| Dec 31, 2020 | 1.72B | 22.31% |
| Dec 31, 2019 | 1.41B | -18.98% |
| Dec 31, 2018 | 1.74B | 51.27% |
| Dec 29, 2017 | 1.15B | 565.31% |
| Dec 30, 2016 | 172.40M | 255.46% |
| Dec 31, 2015 | 48.50M | -83.19% |
| Dec 31, 2014 | 288.60M | -20.30% |
| Dec 31, 2013 | 362.10M | -35.14% |
| Dec 31, 2012 | 558.30M | 141.48% |
| Dec 30, 2011 | 231.20M | -6.85% |
| Dec 31, 2010 | 248.20M | 44.39% |
| Dec 31, 2009 | 171.90M | -17.20% |
| Dec 31, 2008 | 207.60M | -8.55% |
| Dec 31, 2007 | 227.00M | -21.32% |
| Mar 28, 2007 | 288.50M | - |
View and export this data all the way back to 2007. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 965.87B |
| Johnson & Johnson | 500.07B |
| AbbVie | 407.98B |
| UnitedHealth Group | 297.97B |
| AstraZeneca | 287.56B |
| Novartis AG | 266.91B |
| Merck & Co. | 264.63B |
| Novo Nordisk | 229.27B |